title: Skeletal health in adults with HIV infection.
abstract: Concern has been raised that HIV infection, its treatment, or both adversely affect skeletal health. Cross-sectional studies show that bone mineral density (BMD) is 3-5% lower in patients infected with HIV than in uninfected controls, but patients with HIV infection are, on average, 5 kg lighter than uninfected people. After this weight difference is accounted for, BMD differences are smaller and not clinically relevant. Longitudinal studies show short-term BMD loss of 2-4% over 1-2 years when antiretroviral therapy is started, followed by longer periods of BMD increase or stability. Losses are greatest with treatment regimens that contain tenofovir. Patients infected with HIV have slightly higher fracture rates than controls, but the increased risk of fracture is substantially attenuated by adjustment for traditional risk factors for fracture. These reassuring findings suggest that management of skeletal health in HIV should follow guidelines for the general population. In general, effective antiretroviral treatment and avoidance of undernutrition are the two most important factors for maintenance of skeletal health in patients infected with HIV.
authors.affiliation: Department of Medicine, University of Auckland, Auckland, New Zealand. Electronic address: m.bolland@auckland.ac.nz.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Bolland
authors.affiliation: Department of Medicine, University of Auckland, Auckland, New Zealand.
authors.forename: Andrew
authors.initials: A
authors.lastname: Grey
authors.affiliation: Department of Medicine, University of Auckland, Auckland, New Zealand.
authors.forename: Ian R
authors.initials: IR
authors.lastname: Reid
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000009:adverse effects; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism; D002986:Clinical Trials as Topic; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D008297:Male; D012307:Risk Factors
chemical_list: D044966:Anti-Retroviral Agents